BMGL revenueFY2026SGD 16.44M
- FY YoY
- +45.2%
BMGL revenue was SGD 16.44M for fiscal 2026 (ended Jun 30, 2026), up 45.2% from fiscal 2025.
Basel Medical Group Ltd (BMGL) financials
For fiscal 2026 (ended Jun 30, 2026), Basel Medical Group Ltd reported SGD 16.44M of revenue and -SGD 748.0K of net income. Figures are in SGD, the currency of its SEC filings.
- Revenue, FY2026
- SGD 16.44M
- Revenue growth, YoY
- +45.2%
- Net income, FY2026
- -SGD 748.0K
- Net margin
- -4.5%
- Free cash flow, FY2026
- -SGD 883.4K
- EPS, diluted, FY2026
- -SGD 0.78
- Cash
- SGD 529.9K
- Total debt
- SGD 12.05M
FY2024FY2026
FY2024FY2026
FY2024FY2026
BMGL revenue and earnings growth
BMGL net incomeFY2026-SGD 748.0K
BMGL net income was -SGD 748.0K for fiscal 2026 (ended Jun 30, 2026), compared with -SGD 10.64M in fiscal 2025.
BMGL EPSFY2026-SGD 0.78
BMGL diluted EPS was -SGD 0.78 for fiscal 2026 (ended Jun 30, 2026).
BMGL free cash flowFY2026-SGD 883.4K
BMGL free cash flow was -SGD 883.4K for fiscal 2026 (ended Jun 30, 2026), compared with -SGD 4.60M in fiscal 2025.
Income statement
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 |
|---|---|---|---|
| Revenue | SGD 16.44M | SGD 11.32M | SGD 10.05M |
| Interest expense | SGD 459.3K | SGD 203.9K | SGD 176.2K |
| Pre-tax income | -SGD 1.25M | -SGD 11.05M | SGD 2.40M |
| Income tax | SGD 179.6K | -SGD 417.4K | SGD 331.8K |
| Net income | -SGD 748.0K | -SGD 10.64M | SGD 2.07M |
| EPS, basic | -SGD 0.78 | -SGD 0.57 | SGD 0.13 |
| EPS, diluted | -SGD 0.78 | -SGD 0.57 | SGD 0.13 |
| Diluted shares | 1.6M | 18.8M | 16.3M |
Balance sheet
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 |
|---|---|---|---|
| Cash and equivalents | SGD 529.9K | SGD 3.04M | SGD 1.95M |
| Receivables | SGD 10.34M | SGD 9.49M | SGD 2.01M |
| Inventory | SGD 230.9K | SGD 489.1K | SGD 72.0K |
| Current assets | SGD 12.13M | SGD 13.29M | SGD 16.17M |
| Goodwill | SGD 10.35M | SGD 10.35M | - |
| Total assets | SGD 17.79M | SGD 18.68M | SGD 16.31M |
| Current liabilities | SGD 9.86M | SGD 10.16M | SGD 7.16M |
| Short-term debt | SGD 8.66M | SGD 5.08M | SGD 4.29M |
| Long-term debt | SGD 3.39M | SGD 2.96M | SGD 1.58M |
| Total debt | SGD 12.05M | SGD 8.03M | SGD 5.87M |
| Total liabilities | SGD 13.25M | SGD 13.24M | SGD 8.75M |
| Shareholders' equity | SGD 4.54M | SGD 5.44M | SGD 7.56M |
Cash flow
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 |
|---|---|---|---|
| Operating cash flow | -SGD 635.2K | -SGD 4.04M | SGD 2.51M |
| Capital expenditures | SGD 248.2K | SGD 556.9K | SGD 7.9K |
| Free cash flow | -SGD 883.4K | -SGD 4.60M | SGD 2.50M |
| Investing cash flow | -SGD 104.2K | -SGD 10.90M | -SGD 7.9K |
| Financing cash flow | -SGD 1.78M | SGD 16.50M | -SGD 1.77M |
| Stock-based compensation | SGD 300.0K | - | - |
Key ratios
Source: XBRL data Basel Medical Group Ltd files with the SEC, latest filing dated Oct 30, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
BMGL peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| BMGL | SGD 16.44M | +45.2% | -SGD 748.0K | -4.5% | $26.2M |
| BTSG | $15.25B | +26.0% | $410.27M | 2.7% | $14.42B |
| CHE | $2.66B | +5.2% | $282.40M | 10.6% | $7.09B |
| LFST | $1.68B | +22.6% | $71.91M | 4.3% | $5.54B |
| OPCH | $5.75B | +4.0% | $215.19M | 3.7% | $4.74B |
| HIMS | $2.87B | +29.8% | -$190.84M | -6.7% | $4.46B |
| PRVA | $2.43B | +19.2% | $36.08M | 1.5% | $3.11B |
| AVAH | $2.60B | +19.5% | $274.76M | 10.6% | $2.88B |
| ADUS | $1.50B | +11.5% | $111.05M | 7.4% | $2.35B |
BMGL FAQ
8 questionsWhat is BMGL revenue?
Basel Medical Group Ltd (BMGL) reported SGD 16.44M of revenue for fiscal 2026 (ended Jun 30, 2026). That is up 45.2% from the year before.Is BMGL profitable?
No. Basel Medical Group Ltd reported a net loss of SGD 748.0K for fiscal 2026 (ended Jun 30, 2026).How much cash and debt does BMGL have?
Basel Medical Group Ltd reported SGD 529.9K in cash and cash equivalents and SGD 12.05M of debt on its most recent balance sheet in SEC filings.How fast is BMGL revenue growing?
Basel Medical Group Ltd's revenue changed +45.2% in fiscal 2026, to SGD 16.44M.What is BMGL free cash flow?
Basel Medical Group Ltd generated -SGD 883.4K of free cash flow for fiscal 2026 (ended Jun 30, 2026), which is operating cash flow of -SGD 635.2K less capital expenditures.What is BMGL earnings per share?
Diluted earnings per share were -SGD 0.78 for fiscal 2026 (ended Jun 30, 2026), from SEC filings, restated for any stock split those filings show.When did BMGL last report financial results?
The latest statements here come from Basel Medical Group Ltd's 20-F filed on Oct 30, 2026, covering the period ended Jun 30, 2026.Where does this BMGL financial data come from?
Quantisnow builds these statements from the structured XBRL data Basel Medical Group Ltd files with the SEC. It is provided for information only and is not investment advice.